- Home
- RDI vs QNTM Comparison
RDI vs QNTM Comparison
Compare RDI & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- QNTM
- Stock Information
- Founded
- RDI 1937
- QNTM 1998
- Country
- RDI United States
- QNTM Canada
- Employees
- RDI N/A
- QNTM N/A
- Industry
- RDI Movies/Entertainment
- QNTM
- Sector
- RDI Consumer Discretionary
- QNTM
- Exchange
- RDI Nasdaq
- QNTM NYSE
- Market Cap
- RDI 30.1M
- QNTM 35.6M
- IPO Year
- RDI N/A
- QNTM N/A
- Fundamental
- Price
- RDI $1.38
- QNTM $13.46
- Analyst Decision
- RDI Hold
- QNTM
- Analyst Count
- RDI 1
- QNTM 0
- Target Price
- RDI $2.40
- QNTM N/A
- AVG Volume (30 Days)
- RDI 38.2K
- QNTM 210.7K
- Earning Date
- RDI 05-15-2025
- QNTM 05-14-2025
- Dividend Yield
- RDI N/A
- QNTM N/A
- EPS Growth
- RDI N/A
- QNTM N/A
- EPS
- RDI N/A
- QNTM N/A
- Revenue
- RDI $205,644,000.00
- QNTM N/A
- Revenue This Year
- RDI $9.74
- QNTM N/A
- Revenue Next Year
- RDI $6.39
- QNTM N/A
- P/E Ratio
- RDI N/A
- QNTM N/A
- Revenue Growth
- RDI N/A
- QNTM N/A
- 52 Week Low
- RDI $1.17
- QNTM $2.70
- 52 Week High
- RDI $1.89
- QNTM $23.81
- Technical
- Relative Strength Index (RSI)
- RDI 52.10
- QNTM 73.02
- Support Level
- RDI $1.34
- QNTM $10.75
- Resistance Level
- RDI $1.49
- QNTM $13.44
- Average True Range (ATR)
- RDI 0.08
- QNTM 1.39
- MACD
- RDI 0.00
- QNTM 0.22
- Stochastic Oscillator
- RDI 32.35
- QNTM 83.46
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.